Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With Biliary Tract Cancer
NCT05254847Phase 2Completed
- Sponsor
- Fudan University
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, lenvatinib, tislelizumab in biliary tract cancer (BTC), sponsored by Fudan University. Started Feb 2022; status: completed.
02
Drugs
capecitabinelenvatinibtislelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05254847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254847.